Cambridge Healthtech Institute’s 12th Annual

Protein-Protein Interactions
( 蛋白质间交互作用 )

Targeting PPIs and Nucleic Acid Complexes for Therapeutic Interventions


Modulating disease-relevant protein-protein interactions (PPIs) or protein-nucleic acid complexes by chemical agents is a strategy for discovering new compounds with therapeutic potential. However intracellular PPIs are harder to rationally design drugs against or screen in a traditional high-throughput biochemical assay than are traditional intracellular targets such as enzymes. PPIs lack an active site to target. Nevertheless, PPI-targeted drug discovery is moving forward. In fact, the first PPI-targeted drug (against the BCL2 complex) was launched a few years ago for cancer and a few more PPIs are the targets of drug candidates in clinical development. Join your drug discovery peers at Cambridge Healthtech Institute's 12th annual Protein-Protein Interactions conference to discuss innovations and challenges in the field of PPI-directed drug discovery.

Coverage will include, but is not limited to:


  • Identifying ‘hot-spots’ or ‘ligandable features’ of PPIs
  • Improved biophysical tools for PPI-based drug discovery
  • Fragment-based drug design (FBDD) case studies against PPIs
  • Measuring protein conformational challenges/finding allosteric inhibitors
  • Promising PPI targets (MDM2, p53, BCL1, myc, ras, ubiquitin complexes)
  • RNA as drug targets
  • PPI-targeted compounds in development
  • Lead optimization of agents targeting PPIs
  • PPI success stories

* 活动内容有可能不事先告知作更动及调整。